Cardiff Oncology, Inc. short interest in 2023
In 2023, Cardiff Oncology, Inc.'s disclosed short interest ran from 2.24% of shares outstanding on 13 Jan 2023 to 2.95% on 29 Dec 2023, a change of +0.71 percentage points. The year's high was 3.64% on 31 Oct 2023 and its low 1.10% on 14 Jul 2023, averaging 1.93% across 23 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 11.11 days on 30 Nov 2023. Full history: Cardiff Oncology, Inc..
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 2.24% (13 Jan 2023)
- End of year
- 2.95% (29 Dec 2023)
- Change
- +0.71 pp
- High
- 3.64% (31 Oct 2023)
- Low
- 1.10% (14 Jul 2023)
- Average
- 1.93%
- Highest days to cover
- 11.11 (30 Nov 2023)
- SEC filings marked
- 8
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 2.24% | 4.16 | |
| 31 Jan 2023 | 2.03% | 3.07 | |
| 15 Feb 2023 | 1.79% | 2.93 | |
| 28 Feb 2023 | 1.53% | 4.09 | |
| 15 Mar 2023 | 1.51% | 2.83 | 10-K filed, results (8-K) |
| 31 Mar 2023 | 1.40% | 2.49 | |
| 14 Apr 2023 | 1.41% | 3.57 | |
| 28 Apr 2023 | 1.38% | 3.57 | |
| 15 May 2023 | 1.21% | 2.77 | 10-Q filed, results (8-K) |
| 31 May 2023 | 1.21% | 4.70 | |
| 15 Jun 2023 | 1.19% | 4.66 | |
| 30 Jun 2023 | 1.20% | 3.08 | |
| 14 Jul 2023 | 1.10% | 3.60 | |
| 31 Jul 2023 | 1.16% | 3.03 | |
| 15 Aug 2023 | 1.49% | 1.00 | 10-Q filed, results (8-K) |
| 31 Aug 2023 | 1.20% | 3.62 | |
| 15 Sep 2023 | 1.51% | 3.31 | |
| 13 Oct 2023 | 3.42% | 3.26 | |
| 31 Oct 2023 | 3.64% | 6.51 | |
| 15 Nov 2023 | 3.57% | 6.32 | 10-Q filed, results (8-K) |
| 30 Nov 2023 | 3.24% | 11.11 | |
| 15 Dec 2023 | 3.02% | 9.81 | |
| 29 Dec 2023 | 2.95% | 7.86 |
See also: Cardiff Oncology, Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.